AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO

EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135)

MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS

DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS

WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE

RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING

LENALIDOMIDE AND A PROTEASOME INHIBITOR